Preferred Label : EGFR Mutant-selective Inhibitor H002;
NCIt synonyms : EGFR Inhibitor H002;
NCIt definition : A fourth-generation, orally bioavailable, mutant-selective epidermal growth factor
receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration,
EGFR mutant-selective inhibitor H002 targets, binds to, and inhibits the activity
of EGFR, including multiple EGFR resistance mutations, such as single mutations, including
Del19 and L858R, double mutations, including Del19/C797S, L858R/C797S, Del19/T790M
and L858R/T790M, and triple mutations, including Del19/T790M/C797S and L858R/T790M/C797S.
This prevents EGFR mutant-mediated signaling, which induces cell death and inhibits
tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase
that is mutated in many tumor cell types, plays a key role in tumor cell proliferation
and tumor vascularization.;
Molecule name : H-002; H 002;
NCI Metathesaurus CUI : CL1905143;
Origin ID : C191847;
UMLS CUI : C5784739;
Semantic type(s)
- concept_is_in_subset
- has_target
